Navigation Links
Erroneous Laboratory Operation May Lead To a Cancer Drug

An error in the laboratory may pave way to the discovery of a new drug for cancer. This was disclosed by Katherine Schaefer of Rochester University Medical Center. //This may be a foundation study for treatments associated with colon, skin, liver and oesophagal cancers.

Schaefer was studying to locate therapeutic measures for swelling in Crohn’s disease and ulcerative colitis which results in intense pain and diarrhoea. Cancer cells were used as controls for this study and a compound by the name PPAR-gamma modulator was being tested. Schaefer realized that a small error in her laboratory calculation resulted in the death of the cancer cells.

She also found that PPAR-gamma had killed all the epithelial lining of the tumor cells. In the mice this compound killed colon tumor with no side effects.

According to Schaefer, mode of action of PPAR-gamma is different from the current drugs. It attacks a section of cell cytoskeleton called tubulin. While tubulin is involved in building the cell arrangement, PPAR-gamma breaks it down. This indirectly indicates that the gamma compound could actually counter the effect of tumor cells to chemotherapy.

Schaefer also intends to pursue this study further and conduct more trials with mice on the same subject.
JYT
'"/>




Page: 1

Related medicine news :

1. Watch Out For the Erroneous Readings in the Glucose Meters
2. Medicare Sends out Reimbursement Checks Erroneously
3. Laboratory Testing Can Identify Risk of Pre-Term Labor and Delivery
4. Laboratory grown vegetarian meat
5. Mexico and US border attain a new outlook due to BiNational Sustainability Laboratory
6. Laboratory Heart valve to study Heart diseases
7. NCFAD Nominated As Reference Laboratory for Bird Flu and BSE
8. British Laboratory Certifies Coke as Safe
9. India to Set Up Nicotine-Mapping Laboratory
10. A Laboratory Filtration System Kills 100 Percent Of Dangerous Microbes In Water
11. Death Of Woman Following Family Planning Operation Creates Panic
Post Your Comments:
(Date:5/16/2008)... Healthy Back Acquires Rival JoAnne,s Bed & Back... Largest Company Owned Back Retail Chain, LORTON,...year old,company whose focus on home and workplace...s acquired all substantial assets of its rival,Jo...ommerce division,claimed 2007 revenues of $40milli...
(Date:5/16/2008)... Consumers could report side effects, but critics ...RIDAY, May 16 (HealthDay News) -- Direct-to-consum...ee phone number that would allow consumers to repo...sted Friday. , The experts serve on a panel tha...uch phone numbers are already mandated by the FDA ...
(Date:5/16/2008)..., A new study being presented at the American Soc...ract #4020), may change treatment practice in abou...the basis for proposed changes to the way colorect...sing National Cancer Institute (NCI) SEER populati...nd phase III clinical trial data, shows that outco...
(Date:5/16/2008)..., Small fibroids located just beneath the lining ... to the endometrial cavity after uterine artery em...lications, according to a new study. , The stud...went an MRI examination before and after UAE. The ...hese, 33% migrated to the endometrial cavity after...
Breaking Medicine News(10 mins):Health News:The Back Wars Come to a Close 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3
...st feel the heart in their mouth when they read th... of suffering a heart attack have finally been id... the Journal Science, has shown that one fifth of ...h doubles their chances of suffering a heart attac...
...erapy is a new innovation in treating severe and c...for frequent and stressful dressing changes. A ne...t this technique has a wide range of applications ...g. This wound therapy is usually delivered via a ...
...antation is quite young, substantial advancements ...een the supply of organs and the demand for them....inates the nation's transplant system through a po...time, sensitization and HLA matching. When a mat...
...d man and his three physically challenged sons hav...their lives , saying there seemed to be little ho...ng hand, death is probably a wise option," says 70... resident of Kamalpur village in Bhadrak district....
Other Medicine News:Health News:The DNA That Spells Double Risk of Heart Attack 2Health News:Who Receives a Kidney Transplant First? 2Health News:70-year-old, Three Sons Seek Mercy Death 2
(Date:5/15/2008)... WOODCLIFF LAKE, N.J., May 15 /- Eisa...t results from 16 clinical data abstracts about,co...t portfolio and,preclinical oncology research have... Meeting of the American Society of Clinical Oncol... June 3, 2008., A wide variety of abstracts on Ei...
(Date:5/15/2008)...hase II Data Presented at ASCO Showed Acceptable T...e of Grade 3 and 4 Neuropathy, WOODCLIFF LAKE, N....motherapeutic agent eribulin mesylate (E7389) demo...on of women with locally advanced or metastatic,br...r Phase II clinical,trial. The study also suggests...
(Date:5/15/2008)... BRIDGEWATER, N.J., May 15 /PRNewswire-FirstCall/ ...nounced today that findings from the,landmark ATHE...al therapy,for the treatment of patients with atri...isk of cardiovascular hospitalizations or death fr...=0.00000002), meeting the study,primary endpoint. ...
(Date:5/15/2008)... BONITA SPRINGS, Fla., May 15 /- Tigr...tion of a Cooperative Research and,Development Agr...(NCI) to,collaborate on clinical and preclinical d...n Phase I development. AFP-464 is converted to,met...n p53 activation and,apoptosis., This is part of ...
Breaking Medicine Technology:Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3Chinas biotech industry 3A An Asian dragon is growing 9197 1Chinas biotech industry 3A An Asian dragon is growing 9197 2Chinas biotech industry 3A An Asian dragon is growing 9197 3Chinas biotech industry 3A An Asian dragon is growing 9197 4Chinas biotech industry 3A An Asian dragon is growing 9197 5Chinas biotech industry 3A An Asian dragon is growing 9197 6Chinas biotech industry 3A An Asian dragon is growing 9197 7Hybridization partially restores vision in cavefish NYU study finds 1800 1Hybridization partially restores vision in cavefish NYU study finds 1800 2Zimmer Holdings Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results 9196 1Most Medicare Drug Plans Continue to Hike Costs into 2008 Two to Three Times Rate of Inflation 9193 1Most Medicare Drug Plans Continue to Hike Costs into 2008 Two to Three Times Rate of Inflation 9193 2Most Medicare Drug Plans Continue to Hike Costs into 2008 Two to Three Times Rate of Inflation 9193 3
...y being treated with maximally,tolerated lipid-low... in LDL-C with similar reductions in other atherog...W ORLEANS, and CARLSBAD, Calif., March 26, 2007,/P... announced,results from its ongoing Phase 2 clinic...s familial hypercholesterolemia (HoFH),presented ...
...atients receiving both Tekturna and,Diovan reached...ng,either agent alone, EAST HANOVER, N.J., March 2...ave shown patients taking two Novartis cardiovascu...ekturna(R),(aliskiren) and the leading therapy Dio...ns in blood pressure levels than those,using eithe...
Other Medicine Technology:Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 2Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 3Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 4Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 5Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 6Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan 2Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan 3Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan 4Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan 5Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan 6
Rapid turn-around time, results in less than 4 hours
Bio-Rad isotopic anemia assays feature standardized protocols and minimal ,pipetting steps for greater efficiency. Clear information about the processes ,involved in isotopic testing and the benefit
Bio-Rad isotopic anemia assays feature standardized protocols and minimal ,pipetting steps for greater efficiency. Clear information about the processes ,involved in isotopic testing and the benefit
... test system is a qualitative screening assay desi...man sera. When performed according to the directio...ng all ANAs commonly tested for, such as those aga..., SSA, SSB, and Scl-70. The test is also capable o...
Medicine Products: